10,792 Shares in AtriCure, Inc. (NASDAQ:ATRC) Bought by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC bought a new position in AtriCure, Inc. (NASDAQ:ATRC) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,792 shares of the medical device company’s stock, valued at approximately $330,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Johnson Financial Group Inc. raised its stake in AtriCure by 1,184.1% in the 4th quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company’s stock worth $49,000 after acquiring an additional 1,492 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in AtriCure in the 4th quarter worth $60,000. Venturi Wealth Management LLC raised its stake in AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after acquiring an additional 2,100 shares during the last quarter. KBC Group NV raised its stake in AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after acquiring an additional 932 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of AtriCure by 232.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,871 shares of the medical device company’s stock valued at $88,000 after buying an additional 2,008 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

Shares of AtriCure stock opened at $32.71 on Monday. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The business has a 50-day moving average price of $32.40 and a 200 day moving average price of $34.85. The firm has a market cap of $1.62 billion, a PE ratio of -34.43 and a beta of 1.57.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The company had revenue of $123.62 million for the quarter, compared to analysts’ expectations of $122.92 million. During the same period in the previous year, the firm posted ($0.28) EPS. AtriCure’s revenue was up 13.5% compared to the same quarter last year. Sell-side analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Piper Sandler lifted their price objective on AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Oppenheimer lifted their price objective on AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and set a $60.00 price objective on shares of AtriCure in a research note on Wednesday, April 30th. UBS Group reduced their price objective on AtriCure from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. Finally, Needham & Company LLC reduced their price objective on AtriCure from $51.00 to $44.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.67.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.